Poxel's Imeglimin Hits Phase II Endpoints in Type II Diabetes
Poxel SA's lead oral diabetes drug, imeglimin, reached the primary endpoint in a Phase II trial in Type II diabetes patients, demonstrating statistically significant decreases in plasma glucose and fasting plasma glucose levels when administered in combination with sitagliptin vs. treatment with sitagliptin alone.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST